Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACLX, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-12-23 | anito-cel | relapsed or refractory multiple myeloma | BLA | 61% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACLX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →